Cladribine and ocrelizumab induce differential miRNA profiles in peripheral blood mononucleated cells from relapsing-remitting multiple sclerosis patients.
Arisi I, Malimpensa L, Manzini V, Brandi R, Gosetti di Sturmeck T, D'Amelio C, Crisafulli S, Ferrazzano G, Belvisi D, Malerba F, Florio R, Pascale E, Soreq H, Salvetti M, Cattaneo A, D'Onofrio M, Conte A.
Arisi I, et al. Among authors: soreq h.
Front Immunol. 2023 Dec 13;14:1234869. doi: 10.3389/fimmu.2023.1234869. eCollection 2023.
Front Immunol. 2023.
PMID: 38152407
Free PMC article.